Karyopharm Therapeutics Inc. reaffirmed earnings guidance for the full year of 2024. For the year, the company expects total revenue to be in the range of $140.0 million to $160.0 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8282 USD | +3.52% | -16.77% | -4.25% |
07-01 | Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) dropped from Russell 2000 Growth Index | CI |
07-01 | Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) dropped from Russell 3000E Growth Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.25% | 99.71M | |
+15.58% | 122B | |
+16.60% | 113B | |
+17.55% | 26.22B | |
-24.33% | 19.01B | |
-19.14% | 15.71B | |
-17.95% | 15.22B | |
-46.81% | 14.72B | |
+58.78% | 14.58B | |
+4.91% | 13.84B |
- Stock Market
- Equities
- KPTI Stock
- News Karyopharm Therapeutics Inc.
- Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year of 2024